Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Production / Operations

Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

By The Northwire Desk — AI Analysis Nov 07, 2025 · 07:00 QNTM · 12.15 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Q3 2025 financials show a 275% increase in shareholder equity to US$7.5 M and an 87% reduction in the debt‑to‑equity ratio to 0.89×, driven by elimination of convertible debenture liabilities.
  • Digital asset portfolio (primarily Bitcoin) generated realized gains of US$572 k; total crypto holdings now valued at US$5.2 M.
  • Clinical progress on Lucid‑21‑302 (Lucid‑MS): Phase 1 oral toxicity studies completed with no safety signals, first MS patient scanned in joint PET study with MGH, and IND preparation agreement signed for FDA filing.

Key Details

  • Balance Sheet Improvements – Total liabilities fell from US$13.2 M to US$6.6 M; current ratio improved from 0.78× to 1.41×; equity‑to‑total‑assets rose from 13% to 53%.
  • Liquidity Outlook – Management states cash on hand is sufficient to fund operations beyond March 2027.
  • Digital Assets – Crypto portfolio valued at US$5.2 M (up from US$0.8 M Dec 31 2024); realized gains of US$572 k recorded in Q3.
  • Lucid‑MS Program – Phase 1 oral toxicity studies (3‑month & 6‑month) completed with no adverse effects; oral formulation selected for upcoming Phase 2 efficacy trial.
  • Partnerships & Agreements –
  • Contract manufacturing agreement signed with a leading CDMO to produce oral Lucid‑MS formulation.
  • Joint PET imaging study with Massachusetts General Hospital initiated; first MS patient scanned.
  • IND preparation services agreement executed with a global CRO for FDA submission.
  • Unbuzzd Wellness Capital Raise – Licensee launched a Reg D 506(c) offering to raise up to US$5 M for growth and potential IPO; the financing is non‑dilutive to Quantum’s equity stake.
  • Health Canada Product License – Granted PN 80144141 for “Qlarity” (energy & metabolism supplement), permitting sales in Canada.
  • Legal Update – Filed memorandum of law opposing CIBC World Markets and RBC Dominion Securities’ joint motion to dismiss the lawsuit alleging stock‑market manipulation; case pending.
  • Special Dividend – Record date October 27 2025; CVR (contingent value rights) distributed on a one‑for‑one basis to Class B Subordinate Voting Shareholders.
  • Warrants – All warrants held by hedge funds have expired post‑Q3.

Notable Quotes

“We have finished the third quarter of 2025 in a stronger position than at close of Q2 2025… our balance sheet is robust, and we are advancing multiple near‑term monetization events.” – Donal Carroll, CFO

“Our MS program is making significant strides; the first patient has undergone PET scanning, and Phase 1 toxicity data confirm safety, positioning us for a Phase 2 trial.” – Donal Carroll, CFO

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other